Distributed Technologies Research Simplifies Global Payments
11.12.2024 10:00:00 CET | Business Wire | Press release
Introduces Revolutionary B2B Payment Solutions
Distributed Technologies Research (DTR), a fintech company focused on simplifying global payments infrastructure, officially launched its technology platform today. DTR seamlessly bridges national payment systems around the world to make financial transactions efficient, secure and universally accessible.
Current payment networks suffer from inefficiencies – such as transfer costs, interchange fees, FX conversion charges, settlement delays and other opaque fees – that effectively act as an indirect tax on consumers worldwide. DTR’s innovative solutions mitigate these inequities with an adaptable, compliant and scalable payment systems architecture that is globally accessible to businesses of all sizes.
“Our team has spent several years studying the systemic barriers within traditional payment systems. The amalgamation of national payments systems with blockchain technologies has the potential to eliminate the hidden tax on consumers,” said Akshay Naheta, Founder & CEO of DTR.
DTR has unveiled AmalgamOS™, a state-of-the-art technology stack designed to streamline money transfers and merchant payments. Leveraging its proprietary International Orchestration Network (ION), AmalgamOS™ enhances financial connectivity and security for businesses worldwide. Currently live and trusted by numerous merchants and corporate clients, AmalgamOS™ enables instant fiat-to-fiat, fiat-to-stablecoin and stablecoin-to-fiat transactions in over 40 countries, with a roadmap into more than 100 countries in 2025.
Key Features of AmalgamOS™:
Enhanced Transaction Speed: Transactions settle in minutes, leveraging blockchains’ 24/7 operational capability.
Cost Efficiency: Reduced reliance on intermediaries drastically lowers transaction fees.
Global Reach: Currently operational for payouts in over 40 countries worldwide, with pay-in capabilities available across EU nations. The platform is consistently expanding, with new countries being added monthly to enhance global reach and accessibility.
Developer-Centric Design: Flexible API’s, easy-to-integrate widgets, comprehensive white-label solutions, and a merchant control panel provide extensive optionality through simple integrations.
DTR’s interdisciplinary team combines seasoned professionals from traditional finance, payment systems, blockchains and Web3 technology. “DTR is dedicated to its goal of redefining the payments ecosystem by fostering inclusivity and eliminating inefficiencies, benefitting millions of people worldwide. By leveraging blockchain technologies for transparency, security and instantaneous settlements, DTR is addressing the growing demand for efficient and scalable payments solutions,” said Naheta.
Stablecoin transaction volume reached $8.5 trillion(1) in the second quarter of 2024 alone, and the global cross-border payments market is projected to grow to $290 trillion by 2030 from $190 trillion in 2023(2). DTR is uniquely positioned to lead this global payment systems transformation.
About Distributed Technologies Research (DTR)
Distributed Technologies Research (DTR) is at the forefront of simplifying how businesses conduct secure and seamless money transfers globally. We connect disparate national payment networks to enable a worldwide, instantaneous payments ecosystem. Our proprietary AmalgamOS™ technology and International Orchestration Network (ION) provide next-generation payments infrastructure and solutions.
For more information, visit http://www.dtr.org/
About Akshay Naheta, Founder & CEO, DTR
Akshay Naheta founded DTR with a vision to simplify financial transactions through the creation of an advanced global payments infrastructure. He brings over 20 years of experience in finance and technology, with an intricate understanding of blockchains, financial markets and payment systems. Previously, he held senior executive roles at SoftBank Group, where he spearheaded numerous technology investments in industry leaders such as ARM, Auto1 and Nvidia.
Sources:
(1) a16z, State of Crypto Report 2024. https://tinyurl.com/yn9wwjzj
(2) FTX Intelligence, Cross-border payments market sizing data. https://tinyurl.com/bdr7nkdv
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210988080/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom